7月29日，Glaukos Corp盘后上涨5.05%，报167.0美元/股，成交额236.89万美元。消息面上，公司于7月27日宣布Preserflo™微型引流器510(k)关键性研究已完成全部患者入组（目标至少110名患者），标志着该产品美国上市进程迈出关键一步；同时公司于当日盘后发布季度财报，此前市场一致预期本季度营收约1.51亿美元、同比增长30.68%，延续高增态势。
机构层面，Truist将目标价从160美元上调至180美元并维持买入评级，Needham亦多次上调目标价；尽管瑞银近日将评级下调至中性，但整体市场情绪偏多，FactSet统计均值目标价为163.85美元。管线进展与财报催化形成共振，推动盘后进一步走高。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.